About 277,306 results
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvem...
JAMA Kaye KS, Bhowmick T et. al.

Feb 27th, 2018 - Meropenem-vaborbactam is a combination carbapenem/beta-lactamase inhibitor and a potential treatment for severe drug-resistant gram-negative infections. To evaluate efficacy and adverse events of meropenem-vaborbactam in complicated urinary tract infection (UTI), including acute pyelonephritis. Phase 3, multicenter, multinational, randomized clinical trial (TANGO I) conducted November 2014 to A...

Risk of post-pregnancy hypertension in women with a history of hypertensive disorders o...
BMJ (Clinical Research Ed.); Behrens I, Basit S et. al.

Jul 13th, 2017 - Objectives To determine how soon after delivery the risk of post-pregnancy hypertension increases in women with hypertensive disorders of pregnancy and how the risk evolves over time.Design Nationwide register based cohort study.Setting Denmark.Populations 482 972 primiparous women with a first live birth or stillbirth between 1995 and 2012 (cumulative incidence analyses), and 1 025 118 women w...

Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney...
Gastroenterology Klatte DCF, Gasparini A et. al.

Jun 6th, 2017 - Proton pump inhibitors (PPI) have been associated with acute kidney injury and recent studies suggest that they may be associated with the risk of chronic kidney disease (CKD). We performed a retrospective analysis using the Stockholm creatinine measurements database, which contains information on diagnoses, dispensation claims, and laboratory test results for all citizens in the Stockholm regi...

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
JNCCN Motzer RJ, et al.

Nov 13th, 2019 - The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non–clear cell renal cell carcinoma, and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize the NCCN Kidney Cancer Panel discussions for the 2020 update to the guidelines regarding initial management and first-lin...

2019 AHA/ACC Clinical Performance and Quality Measures for Adults With High Blood Pressure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures
Circulation: Cardiovascular Quality and Outcomes; Casey E, et al.

Nov 12th, 2019 - In 2018, the Task Force convened the writing committee to begin the process of revising the existing performance measures set for hypertension that had been released in 2011.3 The writing committee also was charged with the task of developing new measures to evaluate the care of patients in accordance with the 2017 Hypertension Clinical Practice Guidelines.4 The writing committee developed a...

Renin-Angiotensin System Inhibitors vs. Other Antihypertensive Drug Classes for Hypertension
American Family Physician; JEFFREY C. LEGGIT, MD

Nov 5th, 2019 - RAS inhibitors have been widely prescribed to treat hypertension; however, it remains unclear whether they are superior to other antihypertensive drugs in terms of clinically relevant outcomes for primary hypertension.

Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis

Oct 23rd, 2019 - Uncertainty remains about the optimal monotherapy for hypertension, with current guidelines recommending any primary agent among the first-line drug classes thiazide or thiazide-like diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, dihydropyridine calcium channel blockers, and non-dihydropyridine calcium channel blockers, in the absence of comorbid indications...

The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: New features and the ‘Ten Commandments’ of the 2019 Guidelines are discussed...
European Heart Journal; Grant, P. et. al.

Oct 13th, 2019 - The prevalence of diabetes continues to increase, with 60 million thought to have diabetes in Europe in 2017 and predictions of more than 600 million individuals with diabetes worldwide by 2045. These numbers carry a huge burden of morbidity and mortality with a high prevalence of microvascular disease affecting the eyes, nerves, and kidneys and macrovascular disease leading to CV, cerebrovascu...

Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease - AMBER

Oct 7th, 2019 - The AMBER trial showed that the potassium binder patiromer was effective at allowing more patients to remain on spironolactone.

Preventive Cardiology as a Subspecialty of Cardiovascular Medicine
Journal of the American College of Cardiology; Shapiro, M. et. al.

Oct 1st, 2019 - Although significant progress has been made to reduce the global burden of cardiovascular disease, efforts have focused primarily on treatment of manifest disease rather than on prevention of events. An enormous opportunity exists to transition focus from intervention to providing equal attention to prevention of cardiovascular disease. The nascent specialty of “preventive cardiology” is emergi...

Protecting Patients from Elder Abuse Scams
American Family Physician;

Sep 30th, 2019 - Living on my own continues to be very important to me, even though I'm getting older and am sometimes forgetful. I manage pretty well with the help of my son, who visits me weekly, and my family doctor, who I see monthly for my hypertension, stomach reflux problems, prediabetes, and high cholesterol. I try to manage my forgetfulness with the help of a pill box so that I remember to take my medi...

U.S. FDA Approves INVOKANA® (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes (T2D) and DKD

Sep 29th, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for INVOKANA® (canagliflozin) to reduce the risk of end-stage kidney disease (ESKD), worsening of kidney function, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes and diabetic kidney disease (nephropa...

Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline

Sep 23rd, 2019 - Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is an extensive update of KDIGO's 2008 guideline on HCV infection in CKD. This update reflects the major advances since the introduction of direct-acting antivirals (DAAs...

Screening for Asymptomatic Bacteriuria in Adults: US Preventive Services Task Force Recommendation Statement

Sep 23rd, 2019 - Importance Among the general adult population, women (across all ages) have the highest prevalence of asymptomatic bacteriuria, although rates increase with age among both men and women. Asymptomatic bacteriuria is present in an estimated 1% to 6% of premenopausal women and an estimated 2% to 10% of pregnant women and is associated with pyelonephritis, one of the most common nonobstetric reaso...

Lipoprotein(a): The Next Promising CVD Risk Assessment Tool and Prevention Target Among the High-risk Population

Sep 17th, 2019 - After low density lipoprotein cholesterol (LDL-C) has been targeted to reduce cardiovascular disease (CVD) risk, other novel lipid biomarkers have become the center of attention of investigation, and on-going clinical trials are targeting these lipid markers trying to lower the so-called "residual CVD risk" in addition to conventional lipid-lowering therapy. Among them, serum lipoprotein(a) [Lp...

Hypertension Scientific Sessions 2019

Sep 6th, 2019 - Hypertension Scientific Sessions 2019, Sept. 5-8, 2019 in New Orleans, LA, explores the latest clinical and basic research on hypertension science.

Hypertension 2019 Scientific Sessions -Final Program

Sep 6th, 2019 - Sponsored and organized by the Council on Hypertension in collaboration Sponsored and organized by the Council on Hypertension in collaboration with the Council on the Kidney in Cardiovascular Disease with the Council on the Kidney in Cardiovascular Disease.

Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study
The Lancet Neurology;

Aug 19th, 2019 - Midlife hypertension confers increased risk for cognitive impairment in late life. The sensitive period for risk exposure and extent that risk is mediated through amyloid or vascular-related mechanisms are poorly understood. We aimed to identify if, and when, blood pressure or change in blood pressure during adulthood were associated with late-life brain structure, pathology, and cognition.

Unraveling the Safety Profile of Proton-Pump Inhibitors
Journal Watch;

Aug 19th, 2019 - Proton-pump inhibitors (PPIs) provide important clinical benefits for many patients. However, observational studies have suggested an association between PPI use and a variety of adverse events, including dementia, osteoporosis, bone fractures, micronutrient deficiencies, pneumonia, spontaneous bacterial peritonitis, kidney disease, and enteric infections. We have observed that some patients wi...

Intensive blood pressure management may preserve brain health

Aug 13th, 2019 - Numerous large, cohort studies have linked midlife hypertension to mild cognitive impairment and dementia later on. Some of these studies found a higher risk of lesions in the brain's white matter in older age among people with high blood pressure in their 50s. The white matter of the brain consists of bundles of axons, which are the thin elongations of neurons. White matter is "white" due to m...